Stem Cells Market Size, Share & Trends Analysis Report By Product (Adult Stem Cells, Human Embryonic Stem Cells), By Application, By Technology, By Therapy, By End Use, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global stem cells market size was exhibited at USD 22.32 billion in 2022 and is projected to hit around USD 68.72 billion by 2032, growing at a CAGR of 11.9% during the forecast period 2023 to 2032.

stem cells market size

Key Pointers:

  • The adult stem cells segment dominated the market and accounted for the largest revenue share of 83.5% in 2022.
  • The clinical trials on stem cell therapies targeting various diseases have resulted in regenerative medicine segment capturing the largest market share of 91.01% in 2022.
  • The cell acquisition segment captured the highest revenue share of 35.9% in 2022. 
  • The allogenic therapy segment captured the largest revenue share of 60.2% in 2022
  • The pharmaceutical and biotechnology companies segment captured the largest revenue share of 53.7% in 2022.
  • North America accounted for the largest revenue share of 44.8% in 2022.

Stem cells Market Report Scope

Report Coverage Details
Market Size in 2023 USD 24.98 Billion
Market Size by 2032 USD 68.72 Billion
Growth Rate from 2023 to 2032 CAGR of 11.9%
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered Product, application, technology, therapy, end-use, region
Regions Covered North America, Europe, Asia-Pacific, Latin America and Middle East & Africa

Stem cells are cells that can differentiate into a variety of other cells, eventually forming organs or tissues. Many studies have been conducted over the years to assess the true potential of stem cells, leading to a variety of applications in the fields of genetic disease treatment, neurological disorders, oncology, and organ regeneration. The market is driven by the rising number of banks, growing focus on increasing therapeutic potential of these products, and extensive research for the development of regenerative medicines, among other factors.

The growing focus on regenerative therapies is fueling market expansion. iPSCs are becoming increasingly popular for the creation of customized cellular therapies, and opening up new possibilities in regenerative medicine. For instance, in September 2020, researchers from Duke-NUS and Monash University discovered the first stem cell that can aid in the treatment of placenta issues during pregnancy. The researchers devised a new method for producing induced trophoblast stem cells that can be used to generate placenta cells. The research will aid in the development of an in-vitro human placenta model and pave the way for future therapies.

Moreover, COVID-19 is acting as a catalyst for promoting the market growth. Several countries such as U.S., China, and Iran, have started conducting clinical trials using cellular therapies for treatment of COVID-19 infections. Furthermore, the use of cell therapy in the treatment of COVID-19 patients has yielded excellent results, which is fueling market expansion. In January 2020, a group of researchers in Beijing, China, tested stem cell treatment on patients to see if it was beneficial against COVID-19. The study found that administering intravenous clinical-grade MSCs to COVID-19 patients during first trial of treatment, improved their functional results and promoted enhanced recovery. 

Increasing prevalence of cancer is one of the key factors contributing to the growth over the forecast period. Failure of combination therapy and chemotherapy for treatment of cancer has led to the shift in preference of physicians from such therapies to autologous and allogeneic stem cell therapy, thereby boosting the growth. Moreover, key market players and the government bodies are continuously investing in cancer research. For instance, in November 2021, California Institute for Regenerative Medicine invested USD 4 million in therapy targeting patients with acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) 

Introduction of novel technologies for the usage and adoption of cell based therapy is expected to boost the growth over the forecast period. Automation in adult stem cell & cord blood processing and storage are the key technologies expected to positively influence the market growth. For instance, various scientists are aiming for the approval of safe, and successful treatments using stem cells in a broad range of diseases. In 2021, companies such as Biotech Cellino invested USD 75 million in an effort to merge Artificial Intelligence technology for the development of automated stem cell manufacturing, that has the ability to regularizing access to cell treatments while aiming to be cost effective. 

On the other hand, high cost of therapy is expected to hinder the market growth. For example, Bio informant, a stem cell research firm, reported that the cost of stem cell therapy ranges between USD 5,000 and USD 8,000 per patient, with some cases costing as much as USD 25,000 or more depending on the complexity of the procedure. Furthermore, restrictions on stem cell research activities have traditionally hampered embryonic stem cell growth, resulting in a meager share of the total market despite its advantages. 

North America accounted for the largest revenue share of 44.8% in 2022. Presence of innovators and key market players has resulted into higher penetration of market products in the region. North America leads the market owing to strong biotechnology industry, presence of key players, extensive R&D and promotion of personalized medicines. The region accounts for the highest revenue share. Moreover, growth in this region can be further attributed to rising government initiative for promoting stem cell therapies. For instance, in March 2020, the government of Canada invested around USD 7 million in regenerative medicine and stem cell research. It will support 9 transnational projects and 4 clinical trials in the country for growing regenerative medicine sector

Some of the prominent players in the Stem cells Market include:

  • Advanced Cell Technology Inc.
  • STEMCELL Technologies Inc.
  • Cellular Engineering Technologies Inc.
  • CellGenix GmbH    
  • PromoCell GmbH
  • Kite Pharma
  • Lonza
  • Cellartis AB
  • Angel Biotechnology
  • Brainstorm Cell Therapeutics
  • Celgene Corporation
  • Osiris Therapeutics
  • Genea Biocells
  • Bioheart Inc.
  • Waisman Biomanufacturing
  • Tigenix
  • Caladrius Biosciences
  • Gamida Cell 

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global stem cells market.

By Product 

  • Adult Stem Cells (ASCs)
    • Hematopoietic
    • Mesenchymal
    • Neural
    • Epithelial/Skin
    • Others
  • Human Embryonic Stem Cells (HESCs)
  • Induced Pluripotent Stem Cells (iPSCs)
  • Very Small Embryonic Like Stem Cells

By Application 

  • Regenerative Medicine
    • Neurology
    • Orthopedics
    • Oncology
    • Hematology
    • Cardiovascular and Myocardial Infraction
    • Injuries
    • Diabetes
    • Liver Disorder
    • Incontinence
    • Others
  • Drug Discovery And Development

By Technology 

  • Cell Acquisition
    • Bone Marrow Harvest
    • Umbilical Blood Cord
    • Apheresis
  • Cell Production
    • Therapeutic Cloning
    • In-vitro Fertilization
    • Cell Culture
    • Isolation
  • Cryopreservation
  • Expansion And Sub-Culture

By Therapy 

  • Autologous
  • Allogenic

By End-user 

  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Cell Banks
  • Academic & Research Institutes

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global stem cells market size was exhibited at USD 22.32 billion in 2022 and is projected to hit around USD 68.72 billion by 2032

The global stem cells market is growing at a compound annual growth rate (CAGR) of 11.9% from 2023 to 2032.

Key factors that are driving the stem cells market growth include the rising number of stem cell banks, the growing focus on increasing the therapeutic potential of these products, and extensive research for the development of regenerative medicines.

Some key players operating in the stem cells market include Advanced Cell Technology Inc., STEMCELL Technologies Inc., PromoCell GmbH, Cellular Engineering Technologies Inc., and others.

Adult stem cells dominated the stem cells market with a share of 83.7% in 2022 owing to their high penetration over other stem cell types and the presence of a substantial number of approved adult stem cell therapies for clinical use.

Chapter 1. Introduction
                    1.1 Market Segmentation & Scope
                        1.1.1 Estimates And Forecast Timeline
                    1.2 Research Technologyology
                    1.3 Information Procurement
                        1.3.1 Purchased Database
                        1.3.2 nova one advisor’s Internal Database
                        1.3.3 Secondary Sources
                        1.3.4 Primary Research
                        1.3.5 Details Of Primary Research
                    1.4 Information or Data Analysis
                        1.4.1 Data Analysis Models
                    1.5 Market Formulation & Validation
                    1.6 Model Details
                        1.6.1 Commodity Flow Analysis
                            1.6.1.1 Approach 1: Commodity flow approach
                            1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
                    1.7 Global Market: CAGR Calculation
                    1.8 Research Assumptions
                    1.9 List of Secondary Sources
                    1.10 List of Primary Sources
                    1.11 Objectives
                        1.11.1 Objective 1:
                        1.11.2 Objective 2:
                    1.12 List Of Abbreviations
Chapter 2 Market Definitions
Chapter 3 Executive Summary
                    3.1 Market Summary
Chapter 4 Global Stem Cells Market Market Variables, Trends, & Scope
                    4.1 Stem Cells Market Lineage Outlook
                        4.1.1 Parent Market Outlook
                    4.2 Penetration and Growth Prospect Mapping
                    4.3 Regulatory Framework
                    4.4 Market Driver Analysis
                        4.4.1 Ongoing Developments In Regenerative Medicine
                        4.4.2 Rising Funds For Accelerating Stem Cell Research
                        4.4.3 Growing Demand For Stem Cell Banking
                        4.4.4 Increasing Prevalence Of Genetic Disorders
                    4.5 Market Restraint Analysis
                        4.5.1 Ethical Concern Related To Stem Cell Research
                        4.5.1 Lack Of A Well-Defined Regulatory Framework In Certain Applications Of Stem Cell
                    4.6 Key Opportunities
                        4.6.1 Demand For Cell & Gene Therapies
                    4.7 Key Challenge
                        4.7.1 Technical Limitations Associated With Manufacturing Processes
                    4.8 Stem Cells Market - Pestle Analysis
                    4.9 Industry Analysis - Porter’s
                    4.10 Major Deals And Strategic Alliances Analysis
                        4.10.1 Joint Ventures
                        4.10.2 Mergers And Acquisitions
                        4.10.3 Licensing And Partnership
                        4.10.4 Technology Collaborations
                        4.10.5 Strategic Divestments
                    4.11 COVID-19 Impact Analysis
Chapter 5 Stem Cells Market - Segment Analysis, by Product, 2018 - 2032
                    5.1 Global Stem Cells Market: Product Movement Analysis
                    5.2 Adult Stem Cells (ASCs)
                        5.2.1 Adult Stem Cells (Ascs) Market Estimates And Forecast, 2018 - 2032
                        5.2.2 Hematopoietic Stem Cells (Blood Stem Cells)
                            5.2.2.1 Hematopoietic stem cells (blood stem cells) market estimates and forecasts, 2018 - 2032
                        5.2.3 Mesenchymal Stem Cells
                            5.2.3.1 Mesenchymal stem cells market estimates and forecasts, 2018 - 2032
                        5.2.4 Neural Stem Cells
                            5.2.4.1 Neural stem cells market estimates and forecasts, 2018 - 2032
                        5.2.5 Epithelial/Skin Stem Cells
                            5.2.5.1 Epithelial/Skin stem cells market estimates and forecasts, 2018 - 2032
                        5.2.6 Other Adult Stem Cells
                            5.2.6.1 Other adult stem cells market estimates and forecasts, 2018 - 2032
                    5.3 Human Embryonic Stem Cells
                        5.3.1 Human Embryonic Stem Cells Market Estimates And Forecast, 2018 - 2032
                    5.4 Induced Pluripotent Stem Cells
                        5.4.1 Induced Pluripotent Stem Cells Market Estimates And Forecast, 2018 - 2032
                    5.5 Very Small Embryonic Like Stem Cells
                        5.5.1 Very Small Embryonic Like Stem Cells Market Estimates And Forecast, 2018 - 2032
Chapter 6 Stem Cells Market- Segment Analysis, by Application, 2018 - 2032
                    6.1 Stem Cells Market: Application Movement Analysis
                    6.2 Regenerative Medicine
                        6.2.1 Regenerative Medicine Market Estimates And Forecast, 2018 - 2032
                        6.2.2 Neurology
                            6.2.2.1 Neurology market estimates and forecasts, 2018 - 2032
                        6.2.3 Orthopedics
                            6.2.3.1 Orthopedics market estimates and forecasts, 2018 - 2032
                        6.2.4 Oncology
                            6.2.4.1 Oncology market estimates and forecasts, 2018 - 2032
                        6.2.5 Hematology
                            6.2.5.1 Hematology market estimates and forecasts, 2018 - 2032
                        6.2.6 Cardiovascular and Myocardial Infraction
                            6.2.6.1 Cardiovascular and myocardial infraction market estimates and forecasts, 2018 - 2032
                        6.2.7 Injuries
                            6.2.7.1 Injuries market estimates and forecasts, 2018 - 2032
                        6.2.8 Diabetes
                            6.2.8.1 Diabetes market estimates and forecasts, 2018 - 2032
                        6.2.9 Liver Disorder
                            6.2.9.1 Liver Disorder market estimates and forecasts, 2018 - 2032
                        6.2.10 Incontinence
                            6.2.10.1 Incontinence market estimates and forecasts, 2018 - 2032
                        6.2.11 Others
                            6.2.11.1 Others market estimates and forecasts, 2018 - 2032
                    6.3 Drug Discovery and Development
                        6.3.1 Drug Discovery And Development Market Estimates And Forecast, 2018 - 2032
Chapter 7 Stem Cells Market - Segment Analysis, by Technology, 2018 - 2032
                    7.1 Global Stem Cells Market: Technology Movement Analysis
                    7.2 Cell Acquisition
                        7.2.1 Cell Acquisition Market Estimates And Forecast, 2018 - 2032
                        7.2.2 Bone Marrow Harvest
                            7.2.2.1 Bone Marrow Harvest market estimates and forecasts, 2018 - 2032
                        7.2.3 Umbilical Blood Cord
                            7.2.3.1 Umbilical Blood Cord market estimates and forecasts, 2018 - 2032
                        7.2.4 Apheresis
                            7.2.4.1 Apheresis market estimates and forecasts, 2018 - 2032
                    7.3 Cell Production
                        7.3.1 Cell Production Market Estimates And Forecast, 2018 - 2032
                        7.3.2 Therapeutic Cloning
                            7.2.3.1 Therapeutic Cloning market estimates and forecasts, 2018 - 2032
                        7.3.3 In Vitro Fertilization
                            7.3.3.1 In Vitro Fertilization market estimates and forecasts, 2018 - 2032
                        7.3.4 Cell Culture
                            7.3.4.1 Cell Culture market estimates and forecasts, 2018 - 2032
                        7.3.5 Isolation
                            7.3.5.1 Isolation market estimates and forecasts, 2018 - 2032
                    7.4 Cryopreservation
                        7.4.1 Cryopreservation Market Estimates And Forecast, 2018 - 2032
                    7.5 Expansion And Sub-Culture
                        7.5.1 Expansion And Sub-Culture Market Estimates And Forecast, 2018 - 2032
Chapter 8 Stem Cells Market - Segment Analysis, By Therapy, 2018 - 2032
                    8.1 Global Stem Cells Market: Therapy Movement Analysis
                    8.2 Autologous
                        8.2.1 Autologous Market Estimates And Forecast, 2018 - 2032
                    8.3 Allogenic
                        8.3.1 Allogenic Market Estimates And Forecast, 2018 - 2032
Chapter 9 Stem Cells Market - Segment Analysis, By End-User, 2018 - 2032
                    9.1 Global Stem Cells Market: End-User Movement Analysis
                    9.2 Pharmaceutical And Biotechnology Companies
                        9.2.1 Pharmaceutical And Biotechnology Companies Market Estimates And Forecast, 2018 - 2032
                    9.3 Hospitals & Cell Banks
                        9.3.1 Hospitals & Cell Banks Market Estimates And Forecast, 2018 - 2032
                    9.4 Academic & Research Institutes
                        9.4.1 Academic & Research Institutes Market Estimates And Forecast, 2018 - 2032
Chapter 10 Stem Cells Market: - Segment Analysis, By Region, 2018 - 2032
                    10.1 Stem Cells Market: Regional Movement Analysis
                    10.2 North America
                        10.2.1 North America Market Estimates And Forecast, 2018 - 2032
                        10.2.2 U.S.
                            10.2.2.1 U.S. market estimates and forecast, 2018 - 2032
                        10.2.3 Canada
                            10.2.3.1 Canada market estimates and forecast, 2018 - 2032
                    10.3 Europe
                        10.3.1 Europe Market Estimates And Forecast, 2018 - 2032
                        10.3.2 U.K.
                            10.3.2.1 U.K. market estimates and forecast, 2018 - 2032
                        10.3.3. Germany
                            10.3.3.1 Germany market estimates and forecast, 2018 - 2032
                        10.3.4 France
                            10.3.4.1 France market estimates and forecast, 2018 - 2032
                        10.3.5. Italy
                            10.3.5.1 Italy market estimates and forecast, 2018 - 2032
                        10.3.5 Spain
                            10.3.5.1 Spain market estimates and forecast, 2018 - 2032
                    10.4 Asia Pacific
                        10.4.1 Asia Pacific Market Estimates And Forecast, 2018 - 2032
                        10.4.2 Japan
                            10.4.2.1 Japan market estimates and forecast, 2018 - 2032
                        10.4.3 China
                            10.4.3.1 China market estimates and forecast, 2018 - 2032
                        10.4.4 India
                            10.4.4.1 India Market Estimates And Forecast, 2018 - 2032
                        10.4.5 South Korea
                            10.4.5.1 South Korea Market Estimates And Forecast, 2018 - 2032
                        10.4.6 Australia
                            10.4.6.1 Australia Market Estimates And Forecast, 2018 - 2032
                    10.5 Latin America
                        10.5.1 Latin America Market Estimates And Forecast, 2018 - 2032
                        10.5.2 Brazil
                            10.5.2.1 Brazil Market Estimates And Forecast, 2018 - 2032
                        10.5.3 Mexico
                            10.5.3.1 Mexico Market Estimates And Forecast, 2018 - 2032
                        10.5.4 Argentina
                            10.5.4.1 Argentina market estimates and forecast, 2018 - 2032
                    10.6 Middle East & Africa (MEA)
                        10.6.1 Middle East & Africa Market Estimates And Forecast, 2018 - 2032
                        10.6.1 South Africa
                            10.6.1.1 South Africa Market Estimates And Forecast, 2018 - 2032
                        10.6.2 Saudi Arabia
                            10.6.2.1 Saudi Arabia market estimates and forecast, 2018 - 2032
                        10.6.3 UAE
                            10.6.3.1 UAE market estimates and forecast, 2018 - 2032
Chapter 11 Competitive Landscape
                    11.1 Public Companies
                        11.1.1 Company Market Position Analysis
                        11.1.2 Competitive Dashboard Analysis
                        11.1.3 Strategic Framework
                    11.2 Private Companies
                        11.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
                        11.2.2 Regional Network Map
                    11.3 Company Profiles
                        11.3.1 ADVANCED CELL TECHNOLOGY, INC.
                            11.3.1.1 Company Overview
                            11.3.1.2 Financial Performance
                            11.3.1.3 Product Benchmarking
                            11.3.1.4 Strategic Initiatives
                        11.3.2 STEMCELL Technologies, Inc.
                            11.3.2.1 Company Overview
                            11.3.2.2 Financial Performance
                            11.3.2.3 Product Benchmarking
                            11.3.2.4 Strategic Initiatives
                        11.3.3 CELLULAR ENGINEERING TECHNOLOGIES INC.
                            11.3.3.1 Company Overview
                            11.3.3.2 Financial Performance
                            11.3.3.3 Product Benchmarking
                            11.3.3.4 Strategic Initiatives
                        11.3.4 CELLGENIX GmbH
                            11.3.4.1 Company Overview
                            11.3.4.2 Financial Performance
                            11.3.4.3 Product Benchmarking
                            11.3.4.4 Strategic Initiatives
                        11.3.5 PROMOCELL GMBH
                            11.3.5.1 Company Overview
                            11.3.5.2 Financial Performance
                            11.3.5.3 Product Benchmarking
                            11.3.5.4 Strategic Initiatives
                        11.3.6 LONZA
                            11.3.6.1 Company Overview
                            11.3.6.2 Financial Performance
                            11.3.6.3 Product Benchmarking
                            11.3.6.4 Strategic Initiatives
                        11.3.7 KITE PHARMA
                            11.3.7.1 Company Overview
                            11.3.7.2 Financial Performance
                            11.3.7.3 Product Benchmarking
                            11.3.7.4 Strategic Initiatives
                        11.3.8 CELLARTIS AB
                            11.3.8.1 Company Overview
                            11.3.8.2 Financial Performance
                            11.3.8.3 Product Benchmarking
                            11.3.8.4 Strategic Initiatives
                        11.3.9 ANGEL BIOTECHNOLOGY
                            11.3.9.1 Company Overview
                            11.3.9.2 Financial Performance
                            11.3.9.3 Product Benchmarking
                            11.3.9.4 Strategic Initiatives
                        11.3.10 BRAINSTORM CELL THERAPEUTICS
                            11.3.10.1 Company Overview
                            11.3.10.2 Financial Performance
                            11.3.10.3 Product Benchmarking
                            11.3.10.4 Strategic Initiatives
                        11.3.11 CELGENE CORPORATION
                            11.3.11.1 Company Overview
                            11.3.11.2 Financial Performance
                            11.3.11.3 Product Benchmarking
                            11.3.11.4 Strategic Initiatives
                        11.3.12 OSIRIS THERAPEUTICS, INC.
                            11.3.12.1 Company Overview
                            11.3.12.2 Financial Performance
                            11.3.12.3 Product Benchmarking
                            11.3.12.4 Strategic Initiatives
                        11.3.13 GENEA BIOCELLS
                            11.3.13.1 Company Overview
                            11.3.13.2 Financial Performance
                            11.3.13.3 Product Benchmarking
                            11.3.13.4 Strategic Initiatives
                        11.3.14 BIOHEART INC.
                            11.3.14.1 Company Overview
                            11.3.14.2 Financial Performance
                            11.3.14.3 Product Benchmarking
                            11.3.14.4 Strategic Initiatives
                        11.3.15 WAISMAN BIOMANUFACTURING
                            11.3.15.1 Company Overview
                            11.3.15.2 Financial Performance
                            11.3.15.3 Product Benchmarking
                            11.3.15.4 Strategic Initiatives
                        11.3.16 TIGENIX
                            11.3.16.1 Company Overview
                            11.3.16.2 Financial Performance
                            11.3.16.3 Product Benchmarking
                            11.3.16.4 Strategic Initiatives
                        11.3.17 CALADRIUS
                            11.3.17.1 Company Overview
                            11.3.17.2 Financial Performance
                            11.3.17.3 Product Benchmarking
                            11.3.17.4 Strategic Initiatives
                        11.3.18 GAMIDA CELL.
                            11.3.18.1 Company Overview
                            11.3.18.2 Financial Performance
                            11.3.18.3 Product Benchmarking
                            11.3.18.4 Strategic Initiatives
                        11.3.19 PLURISTEM THERAPEUTICS INC.
                            11.3.19.1 Company Overview
                            11.3.19.2 Financial Performance
                            11.3.19.3 Product Benchmarking
                            11.3.19.4 Strategic Initiatives

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers